Spots Global Cancer Trial Database for Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Official Title: A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients
Study ID: NCT03096093
Interventions
Study Description
Brief Summary: This study evaluates four different doses of ACIT-1 for safety and for the ability to raise effective anti-cancer immune responses in patients with pancreatic and other cancers. Approximately half of the patients will have pancreatic cancer and the other half will have other cancers.
Detailed Description: The immune system has an important role in helping prevent cancer by destroying early cancer cells. When cancer does develop antigen-specific immune (T) cells are still present in the blood but are either not responding or are not effective. Vaccines stimulate these T cells to respond and kill cancer cells. ACIT-1 is designed to stimulate tumour antigen-specific T cells to respond and kill cancer cells.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
Contact Details
Name: Daniel H Palmer, MBChB PhD
Affiliation: Clatterbridge Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
